Live
MapmyIndia has raised Rs 311.88 crore in its anchor book, ahead of its initial share sale that opens for public subscription on Thursday and closes on Monday. Foreign portfolio investors including Fidelity, Nomura, Goldman Sachs, Morgan Stanley, Aberdeen, HSBC and White Oak were allocated equity shares by MapmyIndia in the anchor book.
SBI, HDFC, ICICI Prudential, Birla, Nippon, Tata & Sundaram and life insurance companies such as HDFC Life and Tata AIA Life also participated in MapmyIndia’s anchor book. The company informed the bourses that it had allocated 30,19,183 shares at Rs 1033 per share to anchor investors. Out of the total allocation of 30,19,183 equity shares to the anchor investors, 10,06,395 equity shares were allocated to 9 mutual funds through 17 schemes amounting to Rs 103.96 crore, i.e. approx—33 per cent of the total anchor book.
MapmyIndia aims to mop up Rs 1,040 crore through an initial public offering that will sell 18.9 per cent of the equity shares of the firm. This means that the 25-year-old tech company is valued at Rs 5,500 crore in the IPO.
- L&T Shares Trade With Nominal Losses Despite Securing Orders
- Daily vs Weekly SIP: Which Can Supercharge Your Portfolio to the Million-Mark?
- Rail Vikas Nigam Shares Take a Hit Despite Rs 165 Crore Order
- Lupin Shares Gain 1% as Unit Receives EIR Status from USFDA
- Glenmark Unit Signs Exclusive NSCLC Drug Pact with Hansoh Pharma; Shares Drop 1%
MapmyIndia will still be majority-owned by its founders Rakesh Verma and Rashmi Verma, after the IPO — as they will have around 53 per cent shareholding in the company.
- L&T Shares Trade With Nominal Losses Despite Securing Orders
- Daily vs Weekly SIP: Which Can Supercharge Your Portfolio to the Million-Mark?
- Rail Vikas Nigam Shares Take a Hit Despite Rs 165 Crore Order
- Lupin Shares Gain 1% as Unit Receives EIR Status from USFDA
- Glenmark Unit Signs Exclusive NSCLC Drug Pact with Hansoh Pharma; Shares Drop 1%
The mapping company saw its revenue from operations almost double to Rs 100 crore in the six months ended September (H1) compared to Rs 55 crore in the corresponding period last year. Its net profit in H1 od FY22 increased 161 per cent to Rs 47 crore on year on year basis.
Stock Covered in the news
